Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Meta analysis
 
Feedback
Home
c19early.org COVID-19 treatment researchPeginterferon LambdaPeg.. Lambda (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

0 0.25 0.5 0.75 1 1.25 1.5 1.75 2+ Feld (DB RCT) 0% 1.00 [0.07-15.3] hosp. 1/30 1/30 Improvement, RR [CI] Treatment Control Jagannat.. (SB RCT) 0% 1.00 [0.15-6.87] hosp. 2/60 2/60 TOGETHER Reis (DB RCT) 27% 0.73 [0.21-2.58] death 4/931 6/1,018 Tau​2 = 0.00, I​2 = 0.0%, p = 0.71 Early treatment 17% 0.83 [0.31-2.21] 7/1,021 9/1,108 17% lower risk Kim (SB RCT) -200% 3.00 [0.14-63.2] ICU 1/7 0/7 Improvement, RR [CI] Treatment Control Tau​2 = 0.00, I​2 = 0.0%, p = 0.49 Late treatment -200% 3.00 [0.14-63.2] 1/7 0/7 200% higher risk All studies 7% 0.93 [0.37-2.38] 8/1,028 9/1,115 7% lower risk 4 peginterferon lambda COVID-19 studies c19early.org March 2024 Tau​2 = 0.00, I​2 = 0.0%, p = 0.89 Effect extraction pre-specified(most serious outcome, see appendix) Favors peg.. lambda Favors control
The primary positive trial Reis has major anomolies Kelleni. Results from NCT04967430 have not been reported and contact information was deleted in the registry. Submit updates/corrections.
Mar 16
Covid Analysis Peginterferon Lambda for COVID-19: real-time meta analysis of 4 studies
Meta analysis using the most serious outcome reported shows 7% [-138‑63%] lower risk, without reaching statistical significance. Early treatment is more effective than late treatment. Currently all studies are RCTs. 2 studies f..
Nov 6
2023
Tallaksen, E., Do Your Own Research TOGETHER Files 2: Lawsuit reveals FTX bought effective control of TOGETHER trial, part of SBF's dream of a pharma empire
Analysis of legal documents showing that a non-profit controlled by FTX's SBF and a former colleague invested >$50 million in the Together Trial and had the right to potentially control the company. Author notes that incorrect and mislead..
Mar 16
2023
Kelleni, M., Center for Open Science, doi:10.31219/osf.io/5xd6q Peg-interferon Lambda Single Dose Treatment for COVID-19: A Call to Avoid another Hydroxychloroquine Fiasco
Review of critical issues with [Reis]. Author notes that NEJM declined to publish these issues without comment.
Feb 24
2023
Kim et al., Frontiers in Medicine, doi:10.3389/fmed.2023.1095828 Peginterferon lambda for the treatment of hospitalized patients with mild COVID-19: A pilot phase 2 randomized placebo-controlled trial
200% higher ICU admission (p=1), 25% longer hospitalization (p=0.59), and 12% improved viral clearance (p=1). Very small RCT with 14 hospitalized patients in the USA showing no significant differences with peginterferon lambda. Viral load was improved, however 86% of treatment versus 14% of control patients received remdesivir, and the median bas..
Feb 9
2023
Reis et al., New England Journal of Medicine, doi:10.1056/NEJMoa2209760 Early Treatment with Pegylated Interferon Lambda for Covid-19
27% lower mortality (p=0.76), 42% lower hospitalization (p=0.04), and 51% fewer combined hospitalization/ER visits (p=0.003). High-risk outpatient RCT with 931 peginterferon lambda patients and 1,018 control patients, showing significantly lower hospitalization/ER visits with treatment. Single subcutaneous injection. There were 85/931 and 286/1018 patients for w..
Mar 30
2021
Jagannathan et al., Nature Communications, doi:10.1038/s41467-021-22177-1 Peginterferon Lambda-1a for treatment of outpatients with uncomplicated COVID-19: a randomized placebo-controlled trial
no change in hospitalization (p=1), 6% worse recovery (p=0.76), and 14% worse viral clearance (p=0.91). RCT 120 outpatients with mild/moderate COVID-19, showing no significant differences with peginterferon lambda-1a treatment. 180μg subcutaneous peginterferon lambda-1a. NCT04331899.
Nov 12
2020
Feld et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(20)30566-X (date from preprint) Peginterferon lambda for the treatment of outpatients with COVID-19: a phase 2, placebo-controlled randomised trial
75% lower progression (p=0.35) and 66% improved viral clearance (p=0.03). Small outpatient RCT with 30 peginterferon lambda and 30 control patients, showing improved viral clearance with treatment. Single subcutaneous injection of peginterferon lambda 180μg. NCT04354259.
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Thanks for your feedback! Please search before submitting papers and note that studies are listed under the date they were first available, which may be the date of an earlier preprint.
Submit